Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Crohn's diseaseThe Lancet (British edition), 2012-11, Vol.380 (9853), p.1590-1605 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60026-9 ;PMID: 22914295 ;CODEN: LANCAOFull text available |
|
2 |
Material Type: Article
|
Integrin-based therapeutics: biological basis, clinical use and new drugsNature reviews. Drug discovery, 2016-03, Vol.15 (3), p.173-183 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Mar 2016 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2015.10 ;PMID: 26822833Full text available |
|
3 |
Material Type: Article
|
Application of Artificial Intelligence to Gastroenterology and HepatologyGastroenterology (New York, N.Y. 1943), 2020-01, Vol.158 (1), p.76-94.e2 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 0016-5085 ;EISSN: 1528-0012 ;DOI: 10.1053/j.gastro.2019.08.058 ;PMID: 31593701Digital Resources/Online E-Resources |
|
4 |
Material Type: Article
|
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewThe American journal of gastroenterology, 2011-04, Vol.106 (4), p.674-684 [Peer Reviewed Journal]2015 INIST-CNRS ;Copyright Nature Publishing Group Apr 2011 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2011.60 ;PMID: 21407178Full text available |
|
5 |
Material Type: Article
|
Inflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet (British edition), 2007-05, Vol.369 (9573), p.1641-1657 [Peer Reviewed Journal]Elsevier Ltd ;2007 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(07)60751-X ;PMID: 17499606Full text available |
|
6 |
Material Type: Article
|
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel diseaseNature reviews. Gastroenterology & hepatology, 2022-06, Vol.19 (6), p.351-366 [Peer Reviewed Journal]2022. Springer Nature Limited. ;Springer Nature Limited 2022. corrected publication 2022. ;ISSN: 1759-5045 ;EISSN: 1759-5053 ;DOI: 10.1038/s41575-021-00574-7 ;PMID: 35165437Full text available |
|
7 |
Material Type: Article
|
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2021-09, Vol.385 (14), p.1280-1291 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2033617 ;PMID: 34587385Full text available |
|
8 |
Material Type: Article
|
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisThe American journal of gastroenterology, 2015-06, Vol.110 (6), p.802-819 [Peer Reviewed Journal]Copyright Nature Publishing Group Jun 2015 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2015.120 ;PMID: 25964225Full text available |
|
9 |
Material Type: Article
|
Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2019-09, Vol.381 (13), p.1201-1214 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1900750 ;PMID: 31553833Full text available |
|
10 |
Material Type: Article
|
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1606910 ;PMID: 28467869Full text available |
|
11 |
Material Type: Article
|
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysisPloS one, 2018-05, Vol.13 (5), p.e0195123-e0195123 [Peer Reviewed Journal]2018 Singh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Singh et al 2018 Singh et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0195123 ;PMID: 29771924Full text available |
|
12 |
Material Type: Article
|
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisThe New England journal of medicine, 2012-08, Vol.367 (7), p.616-624 [Peer Reviewed Journal]Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1112168 ;PMID: 22894574 ;CODEN: NEJMAGFull text available |
|
13 |
Material Type: Article
|
Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2013-08, Vol.369 (8), p.699-710 [Peer Reviewed Journal]Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215734 ;PMID: 23964932 ;CODEN: NEJMAGFull text available |
|
14 |
Material Type: Article
|
Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England journal of medicine, 2013-08, Vol.369 (8), p.711-721 [Peer Reviewed Journal]Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215739 ;PMID: 23964933 ;CODEN: NEJMAGFull text available |
|
15 |
Material Type: Article
|
The Natural History of Adult Crohn's Disease in Population-Based CohortsThe American journal of gastroenterology, 2010-02, Vol.105 (2), p.289-297 [Peer Reviewed Journal]2015 INIST-CNRS ;Copyright Nature Publishing Group Feb 2010 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2009.579 ;PMID: 19861953Full text available |
|
16 |
Material Type: Article
|
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meetingGut, 2021-04, Vol.70 (4), p.635-640 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0017-5749 ;ISSN: 1468-3288 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2020-324000 ;PMID: 33472895Full text available |
|
17 |
Material Type: Article
|
Treat to Target: A Proposed New Paradigm for the Management of Crohn's DiseaseClinical gastroenterology and hepatology, 2015-06, Vol.13 (6) [Peer Reviewed Journal]Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1542-3565 ;EISSN: 1542-7714 ;DOI: 10.1016/j.cgh.2013.09.006 ;PMID: 24036054Digital Resources/Online E-Resources |
|
18 |
Material Type: Article
|
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBDGastroenterology (New York, N.Y. 1943), 2021-04, Vol.160 (5), p.1452-1460.e21 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 0016-5085 ;EISSN: 1528-0012 ;DOI: 10.1053/j.gastro.2020.10.065 ;PMID: 33421515Digital Resources/Online E-Resources |
|
19 |
Material Type: Article
|
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-AnalysisThe American journal of gastroenterology, 2011-04, Vol.106 (4), p.644-659 [Peer Reviewed Journal]2015 INIST-CNRS ;Copyright Nature Publishing Group Apr 2011 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2011.73 ;PMID: 21407183Full text available |
|
20 |
Material Type: Article
|
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's diseaseGut, 2015-10, Vol.64 (10), p.1539-1545 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 0017-5749 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2014-307883 ;PMID: 25336114 ;CODEN: GUTTAKFull text available |